Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide

British Journal of Pharmacology

Volumn 149, Issue 8, 2006, Pages 988-997

  Damrot, J ^a   Nubel T ^a   Epe, B ^a   Roos, W P ^a   Kaina, B ^a   Fritz, G ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Doxorubicin; Endothelial cells; Etoposide; Genotoxic stress response; HMG CoA reductase inhibitors; Lovastatin

Indexed keywords

CHECKPOINT KINASE 1; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; MEVINOLIN; POISON; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CROSS RESISTANCE; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; ENDOTHELIUM CELL; GENOTOXICITY; HUMAN; HUMAN CELL; OUTCOME ASSESSMENT; PLEIOTROPY; PRIORITY JOURNAL; STRESS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMUTAGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; DNA DAMAGE; DNA REPLICATION; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; ETOPOSIDE; FIBROBLASTS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33845680365     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706953     Document Type: Article

References (66)

1. Adamson P, Marshall CJ, Hall A, Tilbrook PA (1992). Post-translational modifications of p21rho proteins. J Biol Chem 267: 20033-20038.
2. Bachur NR, Yu F, Johnson R, Hickey R, Wu Y, Malkas L (1992). Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol 41: 993-998.
3. Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchars KL et al. (1995). Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 55: 78-82.
4. Cafforio P, Dammacco F, Gernone A, Silvestris F (2005). Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26: 883-891.
5. Canman CE, Kastan MB (1996). Signal transduction. Three paths to stress relief. Nature 384: 213-214.
6. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH (1996). The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 271: 31929-31936.
7. Cheng G, Diebold BA, Hughes Y, Lambeth JD (2006). Nox1-dependent reactive oxygen generation is regulated by Rac1. J Biol Chem 281: 17718-17726.
8. Chow AY, Chin C, Dahl G, Rosenthal DN (2006). Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J Clin Oncol 24: 925-928.
9. Cooper S (2002). Reappraisal of G1-phase arrest and synchronization by lovastatin. Cell Biol Int 26: 715-727.
10. Cortez D, Guntuku S, Qin J, Elledge SJ (2001). ATR and ATRIP: partners in checkpoint signaling. Science 294: 1713-1716.
11. Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N et al. (1995). The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 81: 1137-1146.
12. Cowell IG, Okorokov AL, Cutts SA, Padget K, Bell M, Milner J et al. (2000). Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53. Exp Cell Res 255: 86-94.
13. Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP (2002). Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol 40: 611-617.
14. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH et al. (1999). Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 93: 1308-1318.
15. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH et al. (2001). Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 7: 158-167.
16. Dunkern TR, Wedemeyer I, Baumgartner M, Fritz G, Kaina B (2003). Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair (Amsterdam) 2: 49-60.
17. Duquaine D, Hirsch GA, Chakrabarti A, Han Z, Kehrer C, Brook R et al. (2003). Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase. Vasc Med 8: 101-107.
18. Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S et al. (2004). Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 3: 1207-1214.
19. Faneyte IF, Kristel PM, van de Vijver MJ (2004). Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 24: 2931-2939.
20. Faris M, Kokot N, Latinis K, Kasibhatla S, Green DR, Koretzky GA et al. (1998a). The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J Immunol 160: 134-144.
21. Faris M, Latinis KM, Kempiak SJ, Koretzky GA, Nel A (1998b). Stress-induced Fas ligand expression in T cells is mediated through a MEK kinase 1-regulated response element in the Fas ligand promoter. Mol Cell Biol 18: 5414-5424.
22. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T et al. (2000). Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 6: 2044-2052.
23. Foglesong PD, Reckord C, Swink S (1992). Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol 30: 123-125.
24. Friedberg EC, Wallner GC, Siede W (1995). DNA Repair and Mutagenesis. ASM Press: Washington.
25. Fritz G (2005). HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). Int J Oncol 27: 1401-1409.
26. Fritz G, Kaina B (2006). Late activation of stress kinases (SAPK/JNK) by genotoxins requires the DNA repair proteins DNA-PKcs and CSB. Mol Biol Cell 17: 851-861.
27. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG et al. (2005). Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 112: 1763-1770.
28. Garcia-Escarp M, Martinez-Munoz V, Sales-Pardo I, Barquinero J, Domingo JC, Marin P et al. (2004). Flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs. Cytometry A 62: 129-138.
29. Gnad R, Aktories K, Kaina B, Fritz G (2000). Inhibition of protein isoprenylation impairs Rho-regulated early cellular response to genotoxic stress. Mol Pharmacol 58: 1389-1397.
30. Gnad R, Kaina B, Fritz G (2001). Rho GTPases are involved in the regulation of NF-kB by genotoxic stress. Exp Cell Res 264: 244-249.
31. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ (2004). Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30: 609-641.
32. Hayashi T, Hamakawa K, Nagotani S, Jin G, Li F, Deguchi K et al. (2005). HMG CoA reductase inhibitors reduce ischemic brain injury of Wistar rats through decreasing oxidative stress on neurons. Brain Res 1037: 52-58.
33. Hochhauser D, Valkov NI, Gump JL, Wei I, O'Hare C, Hartley J et al. (1999). Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines. J Cell Biochem 75: 245-257.
34. Hortobagyi GN (1997). Anthracyclines in the treatment of cancer. An overview. Drugs 54 (Suppl 4): 1-7.
35. Jang YM, Kendaiah S, Drew B, Phillips T, Selman C, Julian D et al. (2004). Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett 577: 483-490.
36. Kaneta S, Satoh K, Kano S, Kanda M, Ichihara K (2003). All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 170: 237-243.
37. Koch G, Benz C, Schmidt G, Olenik C, Aktories K (1997). Role of Rho protein in lovastatin-induced breakdown of actin cytoskeleton. J Pharmacol Exp Ther 283: 901-909.
38. Kowalski J, Pawlicki L, Grycewicz J, Blaszczyk J, Irzmanski R, Ceglinski T et al. (2004). Plasma antioxidative activity during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. Fundam Clin Pharmacol 18: 93-96.
39. Kurz EU, Douglas P, Lees-Miller SP (2004). Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 279: 53272-53281.
40. Li H, Junk P, Huwiler A, Burkhardt C, Wallerath T, Pfeilschifter J et al. (2002a). Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation 106: 2250-2256.
41. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM et al. (2002b). Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 277: 15309-15316.
42. Liao JK, Laufs U (2005). Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118.
43. Miyano K, Ueno N, Takeya R, Sumimoto H (2006). Direct involvement of the small GTPase Rac in activation of the superoxide-producing NADPH oxidase Nox1. J Biol Chem 281: 21857-21868.
44. Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S (2005). Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 76: 1439-1453.
45. Muller I, Niethammer D, Bruchelt G (1998a). Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (review). Int J Mol Med 1: 491-494.
46. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M et al. (1998b). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188: 2033-2045.
47. Nuebel T, Damrot J, Roos WP, Kaina B, Fritz G (2006). Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin Cancer Res 12: 933-939.
48. Osterod M, Larsen E, Le Page F, Hengstler JG, Van Der Horst GT, Boiteux S et al. (2002). A global DNA repair mechanism involving the Cockayne syndrome B (CSB) gene product can prevent the in vivo accumulation of endogenous oxidative DNA base damage. Oncogene 21: 8232-8239.
49. Panaretakis T, Laane E, Pokrovskaja K, Bjorklund AC, Moustakas A, Zhivotovsky B et al. (2005). Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Mol Biol Cell 16: 3821-3831.
50. Rao RV, Ellerby HM, Bredesen DE (2004). Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 11: 372-380.
51. Rao S, Lowe M, Herliczek TW, Keyomarsi K (1998). Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17: 2393-2402.
52. Rothkamm K, Lobrich M (2003). Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci USA 100: 5057-5062.
53. Shiloh Y (2001). ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 11: 71-77.
54. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N (2000). Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 207: 77-86.
55. Sordet O, Khan QA, Kohn KW, Pommier Y (2003). Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anticancer Agents 3: 271-290.
56. Tan Y, Dourdin N, Wu C, De Veyra T, Elce JS, Greer PA (2006). Ubiquitous calpains promote caspase-12 and Jnk activation during ER stress-induced apoptosis. J Biol Chem 281: 16016-16024.
57. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984). Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466-468.
58. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ et al. (1996). Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2: 483-491.
59. Urbich C, Dernbach E, Zeiher AM, Dimmeler S (2002). Double-edged role of statins in angiogenesis signaling. Circ Res 90: 737-744.
60. von Bardeleben R, Dunkern T, Kaina B, Fritz G (2002). The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide. Int J Mol Med 10: 473-479.
61. von Bardeleben R, Kaina B, Fritz B (2003). Ultraviolet light-induced apoptotic death is impaired by the HMG-CoA reductase inhibitor lovastatin. Biochem Biophys Res Commun 307: 401-407.
62. Walker K, Olson MF (2005). Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 15: 62-68.
63. Wang CY, Mayo MW, Baldwin Jr AS (1996). TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787.
64. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A et al. (2005). NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112: 3754-3762.
65. Wu X, Hasinoff BB (2005). The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs 16: 93-99.
66. Zhivotovsky B, Orrenius S (2005). Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 331: 859-867.